Needham Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $6
Buy Rating on Geron Driven by EU Approval Prospects and Strategic Commercialization of Rytelo
Geron Analyst Ratings
Stifel Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $8
Geron (GERN) Gets a Buy From Stifel Nicolaus
TD Cowen Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $10
Geron (GERN) Receives a Buy From TD Cowen
Barclays Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $9
Geron Analyst Ratings
H.C. Wainwright Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $9
Scotiabank Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $6
Scotiabank Reaffirms Their Buy Rating on Geron (GERN)
Analysts Offer Insights on Healthcare Companies: Geron (GERN), Merus (MRUS) and C4 Therapeutics (CCCC)
Barclays Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $9
Barclays Initiates Geron(GERN.US) With Buy Rating, Announces Target Price $9
TD Cowen Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $10
Barclays Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $9
Scotiabank Maintains Geron(GERN.US) With Buy Rating, Maintains Target Price $6
A Quick Look at Today's Ratings for Geron(GERN.US), With a Forecast Between $6 to $10
Scotiabank Keeps Their Buy Rating on Geron (GERN)